Clinical Trials

GenitourinaryHead & NeckLymphoid

300 enrolled

Nasopharyngeal Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT07581821 2026-05-12

Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma

33 enrolled

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT04436965 2026-05-11

Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition

266 enrolled

Nasopharyngeal Carcinoma

NCT05340491 2026-05-11

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

212 enrolled

Nasopharyngeal Carcinoma

NCT05941741 2026-05-11

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

380 enrolled

Nasopharyngeal Carcinoma

NCT06197776 2026-05-11

Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC

Recruiting

50 enrolled

Nasopharyngeal Carcinoma, Recurrence

NCT06323239 2026-05-11

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

148 enrolled

Nasopharyngeal Carcinoma

NCT06802835 2026-05-11

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Phase 1/2 Recruiting

148 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT04425265 2026-05-08

Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma

500 enrolled

Nasopharyngeal Carcinoma

NCT03907826 2026-05-07

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

212 enrolled

Nasopharyngeal Carcinoma

NCT06475300 2026-05-06

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

570 enrolled

Head & NeckThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT06532279 2026-05-04

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

98 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Stomatitis

NCT06682442 2026-05-01

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

66 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT04944914 2026-04-30

Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma

188 enrolled

Nasopharyngeal Carcinoma

NCT06662058 2026-04-23

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

118 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03010150 2026-04-15

Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer

Recruiting

471 enrolled

Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms

NCT06093061 2026-04-14

Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

53 enrolled

Nasopharyngeal Carcinoma

NCT07201337 2026-04-06

Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.

700 enrolled

Phase EARLY_PHASE1 Recruiting

Nasopharyngeal Carcinoma

NCT05587543 2026-04-02

Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma

24 enrolled

Nasopharyngeal Carcinoma

NCT06788002 2026-04-02

Light

26 enrolled

Nasopharyngeal Carcinoma

NCT07362979 2026-03-17

Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma

243 enrolled

Nasopharyngeal Carcinoma

NCT07459296 2026-03-16

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

266 enrolled

Nasopharyngeal Carcinoma

NCT07412314 2026-03-09

Proton Therapy for Recurrent Nasopharyngeal Carcinoma

52 enrolled

Nasopharyngeal Carcinoma

NCT06239727 2026-03-06

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

593 enrolled

Nasopharyngeal Carcinoma

NCT06868433 2026-03-04

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Phase 1 Recruiting

40 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT07327216 2026-03-04

Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma

180 enrolled

Nasopharyngeal Carcinoma

NCT06059261 2026-02-18

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

30 enrolled

Nasopharyngeal Carcinoma

NCT06636734 2026-02-11

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

28 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06592599 2026-02-10

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

24 enrolled

Nasopharyngeal Carcinoma

NCT07101744 2026-01-23

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial

41 enrolled

Nasopharyngeal Carcinoma

NCT06976190 2026-01-20

Magic-C002

446 enrolled

Nasopharyngeal Carcinoma, Recurrence

NCT07340515 2026-01-14

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

300 enrolled

Nasopharyngeal Carcinoma

NCT07328841 2026-01-09

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

456 enrolled

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07328854 2026-01-09

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

346 enrolled

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT01365169 2026-01-07

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

GastrointestinalHead & Neck

590 enrolled

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Somatostatinoma, Colorectal Neoplasms

NCT07303023 2025-12-24

INCIPT-NPC

462 enrolled

Nasopharyngeal Carcinoma

NCT07277764 2025-12-11

REDEFINE

23 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT07188584 2025-12-09

Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer

166 enrolled

Nasopharyngeal Carcinoma

NCT07258979 2025-12-02

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

Phase 1/2 Recruiting

202 enrolled

Nasopharyngeal Carcinoma, Recurrence

NCT06839066 2025-11-24

A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy

70 enrolled

Nasopharyngeal Carcinoma

NCT06982300 2025-10-03

NACASOR

Phase 1/2 Recruiting

10 enrolled